Obagi Medical Products Names Preston Romm Chief Financial Officer

LONG BEACH, Calif.--(Business Wire)--
Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical
aesthetic and therapeutic skin health systems, today announced that it
has named Preston Romm, 54, as its Chief Financial Officer, and
Executive Vice President, Finance, Operations and Administration
effective July 1, 2008.

Mr. Romm brings to the Company more than 14 years of senior level
experience in finance, operations and administration including
financing growth strategies, negotiating and integrating several
mergers and acquisitions and implementing restructurings, supply chain
management processes, ERP systems, internal controls and
Sarbanes-Oxley compliance procedures.

Mr. Romm joins Obagi from Iomega Corporation, which recently
completed its sale to EMC Corporation. At Iomega, he was Chief
Financial Officer and responsible for all administrative functions
including finance, SEC compliance, treasury, investor relations and
information systems. Mr. Romm's extensive public company financial
experience includes serving as the CFO of Dot Hill Systems
(NASDAQ:HILL), STM Wireless (NASDAQ:STMI) and Verteq, Inc., a
privately held company, and he was Chief Accounting Officer of MTI
Technology (NASDAQ: MTIC). Mr. Romm began his career at the CPA firm
of Schmidt & Co., and has also held management positions at Unisys and
McDonnell Douglas. He holds a B.S. in Accounting from the University
of Maryland and an M.B.A. from American University. Mr. Romm currently
serves as a member of the board of directors of Netlist (NASDAQ: NLST)
where he is chairman of the audit committee and a member of the
nominating and governance committees.

Steve Carlson, President and CEO of Obagi Medical Products,
stated, "Preston is a welcome addition to Obagi who brings with him
experience overseeing a variety of corporate functions, including
product life cycle assessment, legal and operations in addition to his
extensive financial qualifications. I am particularly impressed with
his track record of driving accountability across the organizations
for which he has been responsible. I believe Preston will play a
significant role as we execute on our growth strategies and build upon
the strong foundation of Obagi Medical Products."

Preston Romm commented, "I appreciate the opportunity that joining
Obagi affords and I look forward to working with Steve and the rest of
his talented team to capitalize on the myriad opportunities in the
aesthetic and dermatology marketplace."

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health
products for the dermatology, plastic surgery, and related aesthetic
markets. Using its Penetrating Therapeutics(TM) technologies, Obagi
Medical's products are designed to improve penetration of agents
across the skin barrier for common and visible skin conditions in
adult skin including chloasma, melasma, senile lentigines, acne
vulgaris and sun damage. The history of Obagi's skin care product
introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx
(the first and only prescription-strength vitamin C and hydroquinone
system), 2004; Obagi(R) Professional-C (a line of highly stable
vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with
cosmetic procedures to enhance patient outcomes and satisfaction,
2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D.
acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R)
M.D. Systems for normal to dry skin, June 2007; and Obagi
ELASTIderm(TM) Decolletage System, January 2008. Obagi's products are
available only through physicians. Visit www.obagi.com for
information.

ICR, Inc.
Ina McGuinness/Lena Adams, 310-954-1100

Copyright Business Wire 2008